Hepatocellular carcinoma: New and emerging risks

Digestive and Liver Disease

Volumn 42, Issue SUPPL. 3, 2010, Pages S215-S222

  Sherman, Morris ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Cirrhosis; Hepatitis B; Hepatitis C; Hepatocellular carcinoma

Indexed keywords

AFLATOXIN; ALPHA FETOPROTEIN; MOLECULAR MARKER; BETA CATENIN; HEPATOCYTE NUCLEAR FACTOR 1;

ARTICLE; BLOOD EXAMINATION; CANCER RISK; CHRONIC HEPATITIS; DIABETES MELLITUS; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER ADENOMA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER HISTOLOGY; LIVER NODULE; METABOLIC SYNDROME X; MIXED INFECTION; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; ADENOMA; AGE; CHRONIC HEPATITIS C; COMPLICATION; DISEASE COURSE; FATTY LIVER; FEMALE; GENETICS; LIVER TUMOR; MALE; MIDDLE AGED; MUTATION; PATHOLOGY; VIROLOGY;

ADENOMA; AGE FACTORS; BETA CATENIN; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; FATTY LIVER; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HEPATOCYTE NUCLEAR FACTOR 1; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUTATION; RISK FACTORS; SEX FACTORS;

EID: 77953723117     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(10)60508-7     Document Type: Article

References (78)

1. Kramer BS General keynote: cancer screening: translation of principles into practice. Gynecol Oncol 2003, 88(1 Pt 2):S71-S74.
2. Anthony PP Liver cell dysplasia: what is its significance?. Hepatology 1987, 7:394-395.
3. Watanabe S, Okita K, Harada T Morphologic studies of the liver cell dysplasia. Cancer 1983, 51:2197-2205.
4. Terminology of nodular hepatocellular lesions. Hepatology 1995, 22:983-993. International Working Party.
5. Lee RG, Tsamandas AC, Demetris AJ Large cell change (liver cell dysplasia) and hepatocellular carcinoma in cirrhosis: matched case-control study, pathological analysis, and pathogenetic hypothesis. Hepatology 1997, 26:1415-1422.
6. Hytiroglou P, Theise ND, Schwartz M, et al. Macroregenerative nodules in a series of adult cirrhotic liver expiants: issues of classification and nomenclature. Hepatology 1995, 21:703-708.
7. Tiniakos DG, Brunt EM Proliferating cell nuclear antigen and Ki-67 labeling in hepatocellular nodules: a comparative study. Liver 1999, 19:58-68.
8. Theise ND, Marcelin K, Goldfischer M, et al. Low proliferative activity in macroregenerative nodules: evidence for an alternate hypothesis concerning human hepatocarcinogenesis. Liver 1996, 16:134-139.
9. Natarajan S, Theise ND, Thung SN, et al. Large-cell change of hepa-tocytes in cirrhosis may represent a reaction to prolonged cholestasis. Am J Surg Pathol 1997, 21:312-318.
10. Terris B, Ingster O, Rubbia L, et al. Interphase cytogenetic analysis reveals numerical chromosome aberrations in large liver cell dysplasia. IHepatol 1997, 27:313-319.
11. Rubin EM, DeRose PB, Cohen C Comparative image cytometric DNA ploidy of liver cell dysplasia and hepatocellular carcinoma. Mod Pathol 1994, 7:677-680.
12. Ueda K, Terada T, Nakanuma Y, et al. Vascular supply in adenomatous hyperplasia of the liver and hepatocellular carcinoma: A morphometric study. HumPathol 1992, 23:619-626.
13. Dutta U, Kench J, Byth K, et al. Hepatocellular proliferation and development of hepatocellular carcinoma: a case-control study in chronic hepatitis C. Hum Pathol 1998, 29:1279-1284.
14. Borzio M, Trere D, Borzio F, et al. Hepatocyte proliferation rate is a powerful parameter for predicting hepatocellular carcinoma development in liver cirrhosis. Mol Pathol 1998, 510:96-101.
15. Arakawa M, Kage M, Sugihara S, et al. Emergence of malignant lesions within an adenomatous hyperplastic nodule in a cirrhotic liver. Observations in five cases. Gastroenterology 1986, 91:198-208.
16. Cameron RG, Greig PD, Farber E, et al. Small encapsulated hepatocellular carcinoma of the liver. Provisional analysis of pathogenic mechanisms. Cancer 1993, 72:2550-2559.
17. Borzio M, Bruno S, Roncalli M, et al. Liver cell dysplasia is a major risk factor for hepatocellular carcinoma in cirrhosis. A prospective study. Gastroenterology 1995, 108:812-817.
18. Ballardini G, Groff P, Zoli M, et al. Increased risk of hepatocellular carcinoma development in patients with cirrhosis and with high hepatocellular proliferation. J Hepatol 1994, 20:218-222.
19. Ganne-Carrie N, Chastang C, Chapel F, et al. Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in Western patients with cirrhosis. Hepatology 1996, 23:1112-1118.
20. Llovet JM, Chen Y, Wurmbach E, et al. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 2006, 131(6):1758-1767.
21. Hoshida Y, Villanueva A, Kobayashi M, et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008, 359(19):1995-2004.
22. Sherman M Recurrence of hepatocellular carcinoma. N Engl J Med 2008, 359(19):2045-2047.
23. Trevisani F, D'Intino PE, Morselli-Labate AM, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 2001, 34:570-575.
24. Sherman M, Peltekian KM, Lee C Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995, 22(2):432-438.
25. Zhou XD, Tang ZY, Fan J, et al. Intrahepatic cholangiocarcinoma: report of 272 patients compared with 5,829 patients with hepatocellular carcinoma. J Cancer Res Clin Oncol 2009, 135(8):1073-1080.
26. Fu K, Kobayashi A, Saito N, et al. Alpha-fetoprotein-producing colon cancer with atypical bulky lymph node metastasis. World J Gastroen-terol 2006, 12(47):7715-7716.
27. Kono K, Amemiya H, Sekikawa T, et al. Clinicopathologic features of gastric cancers producing alpha-fetoprotein. Dig Surg 2002, 19(5):359-365.
28. Natsume T, Watanabe Y, Maruyama T, et al. Successful resection of a liver metastasis from AFP-producing pancreatic cancer resulting in long-term survival: a case report and review of literature. Pancreas 2005, 31(4):416-419.
29. Takahashi Y, Mai M, Ogino T, et al. Clinicopathological study of AFP producing gastric cancer - significance of AFP in gastric cancer. Nippon Geka Gakkai Zasshi 1987, 88(6):696-700.
30. Cottone M, Turri M, Caltagirone M, et al. Screening for hepatocellular carcinoma in patients with Child's A cirrhosis: an 8-year prospective study by ultrasound and alphafetoprotein. J Hepatol 1994, 21(6):1029-1034.
31. Oka H, Tamori A, Kuroki T, et al. Prospective study of alphafetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 1994, 19(1):61-66.
32. Di Bisceglie AM, Sterling RK, Chung RT, et al. HALT-C Trial Group. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol 2005, 43(3):434.
33. Fattovich G, Giustina G, Schalm SW, et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology 1995, 21(1):77-82.
34. Lu SN, Wang JH, Liu SL, et al. Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma. Cancer 2006, 107(9):2212-2222.
35. Beasley RP, Hwang LY, Lin CC, et al. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981, 2(8256):1129-1133.
36. Sun CA, Wu DM, Lin CC, et al. Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan. Am J Epidemiol 2003, 157:674-682.
37. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997, 2:463-472.
38. Bruix J, Barrera JM, Calvert X, et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatitis cirrhosis. Lancet 1989, ii:1004-1006.
39. Niederau C, Lange S, Heintges T, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998, 28:1687-1695.
40. Caballeria L, Pares A, Castells A, et al. Hepatocellular carcinoma in primary biliary cirrhosis: similar incidence to that in hepatitis C virus-related cirrhosis. Am J Gastroenterol 2001, 96(4):1160-1163.
41. Wanless IR, Nakashima E, Sherman M Regression of human cirrhosis: morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med 2000, 124(1l):1599-1607.
42. Nakashima E, Wanless IR Most non-cirrhotic livers with hepatocellular carcinoma (HCC) have evidence of fibrosis or regressed cirrhosis: implications for the pathogenesis of HCC. Hepatology 1999, 30:257A.
43. Ripoll C, Groszmann RJ, Garcia-Tsao G, et al. Portal Hypertension Collaborative Group. Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol 2009, 50(5):923-928.
44. Bañares R, Núñez O, Escudero M, et al. Patients with cirrhosis and bare-stent TIPS may have increased risk of hepatocellular carcinoma. Hepatology 2005, 41(3):566-571.
45. Clifford GM, Rickenbach M, Polesel J, et al. Swiss HIV Cohort. Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. AIDS 2008, 22(16):2135-2141.
46. Giordano TP, Kramer JR, Souchek J, et al. Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: a cohort study, 1992-2001. Arch Intern Med 2004, 164(21):2349-2354.
47. Chen CJ, Yang HI, Su J, et al. REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006, 295(1):65-73.
48. Chen G, Lin W, Shen F, et al. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol 2006, 101(8):1797-1803.
49. Yu MW, Yeh SH, Chen PJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Nati Cancer Inst 2005, 97(4):265-272.
50. Yang HI, Lu SN, Liaw YF, et al. Taiwan Community-Based Cancer Screening Project Group. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002, 347(3):168-174.
51. Yang HI, Yeh SH, Chen PJ, et al. REVEAL-HBV Study Group. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Nati Cancer Inst 2008, 100(16):1134-1143.
52. Chan HL, Hui AY, Wong ML, et al. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 2004, 53(10):1494-1498.
53. Sánchez-Tapias JM, Costa J, Mas A, et al. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology 2002, 123(6):1848-1856.
54. Yuen MF, Tanaka Y, Fong DY, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol 2009, 50(1):80-88.
55. Chen CJ, Yang HI, Iloeje UH, et al. A risk function nomogram for predicting HCC in patients with chronic hepatitis B: The REVEAL-HBV Study. I Hepatol 2007, 46(Suppl 1):S180.
56. Peers FG, Linsell CA Dietary aflatoxins and liver cancer - a population based study in Kenya. Br I Cancer 1973, 27(6):473-484.
57. Zhang IY, Wang X, Han SG, et al. A case-control study of risk factors for hepatocellular carcinoma in Henan, China. Am I Trop Med Hyg 1998, 59(6):947-951.
58. Van Rensburg SI, Cook-Mozaffari P, Van Schalkwyk DI, et al. Hepatocellular carcinoma and dietary aflatoxin in Mozambique and Transkei. Br I Cancer 1985, 51(5):713-726.
59. Ozturk M p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet 1991, 338(8779):1356-1359.
60. Stern MC, Umbach DM, Yu MC, et al. Hepatitis B, aflatoxin B(l), and p53 codon 249 mutation in hepatocellular carcinomas from Guangxi, People's Republic of China, and a meta-analysis of existing studies. Cancer Epidemiol Biomarkers Prev 2001, 10(6):617-625.
61. Collier ID, Carpenter M, Burt AD, et al. Expression of mutant p53 protein in hepatocellular carcinoma. Gut 1994, 35(1):98-100.
62. Fattovich G, Olivari N, Pasino M, et al. Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years. Gut 2008, 57(1):84-90.
63. Matsuoka S, Nirei K, Tamura A, et al. Occult hepatitis B virus infection increases hepatocellular carcinogenesis by eight times in patients with non-B, non-C liver cirrhosis: a cohort study. Intervirology 2008, 51(5):352-361.
64. Ikeda K, Kobayashi M, Someya T, et al. Influence of occult hepatitis B virus coinfection on the incidence of fibrosis and hepatocellular carcinoma in chronic hepatitis C. I Viral Hepat 2009, 16(6):437-443.
65. Raimondo G, Allain IP, Brunetto MR, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. I Hepatol 2008, 49(4):652-657.
66. Michalak TI, Pasquinelli C, Guilhot S, et al. Hepatitis B virus persistence after recovery from acute viral hepatitis. I Clin Invest 1994, 93:230-239.
67. Rehermann B, Ferrari C, Pasquinelli C, et al. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T lymphocyte response. Nat Med 1996, 10:1104-1108.
68. Squadrito G, Pollicino T, Cacciola I, et al. Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients. Cancer 2006, 106(6):1326-1330.
69. Ikeda K, Kobayashi M, Someya T, et al. Occult hepatitis B virus infection increases hepatocellular carcinogenesis by eight times in patients with non-B, non-C liver cirrhosis: a cohort study. I Viral Hepat 2009, 16(6):437-443.
70. Pollicino T, Squadrito G, Cerenzia G, et al. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology 2004, 126(1):102-110.
71. Pollicino T, Raffa G, Costantino L, et al. Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma. Hepatology 2007, 45(2):277-285.
72. Lok AS, Seeff LB, Morgan TR, et al. HALT-C Trial Group. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009, 136(1):138-148.
73. Wang CS, Yao WI, Chang TT, et al. The impact of type 2 diabetes on the development of hepatocellular carcinoma in different viral hepatitis statuses. Cancer Epidemiol Biomarkers Prev 2009, 18(7):2054-2060.
74. Veldt BI, Chen W, Heathcote El, et al. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology 2008, 47(6):1856-1862.
75. Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002, 123(1):134-140.
76. Polesel I, Zucchetto A, Montella M, et al. The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma. Ann Oncol 2009, 20(2):353-357.
77. Paradis V, Zalinski S, Chelbi E, et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 2009, 49(3):851-859.
78. Zucman-Rossi I, Leannot E, Nhieu IT, et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 2006, 43(3):515-524.